Redox Proteomics Analysis of Oxidative Modified Brain Proteins in Alzheimer's Disease and Mild Cognitive Impairment: Insights into the Progression of This Dementing Disorder

Clinical Proteomics: From Diagnosis to Therapy

Volumn , Issue , 2008, Pages 379-401

  Sultana, Rukhsana ^a   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Dementing disorder; Redox proteomics

Indexed keywords

EID: 84889421860     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527622153.ch23     Document Type: Chapter

References (140)

1. Liotta, L. A. and Petricoin, E. F. (2000) Beyond the genome to tissue proteomics. Breast Cancer Research, 2, 13-14.
2. MacBeath, G. (2002) Protein microarrays and proteomics. Nature Genetics, 32 (Suppl.), 526-532.
3. Zhu, H. and Snyder, M. (2003) Protein chip technology. Current Opinion in Chemical Biology, 7, 55-63.
4. Rabilloud, T. (2002) Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics, 2, 3-10.
5. Garbis, S., Lubec, G. and Fountoulakis, M. (2005) Limitations of current proteomics technologies. Journal of Chromatography A, 1077, 1-18.
6. Herbert, B. (1999) Advances in protein solubilisation for twodimensional electrophoresis. Electrophoresis, 20, 660-663.
7. Santoni, V., Molloy, M. and Rabilloud, T. (2000) Membrane proteins and proteomics: un amour impossible?. Electrophoresis, 21, 1054-1070.
8. Marouga, R., David, S. and Hawkins, E. (2005) The development of the DIGE system: 2D fluorescence difference gel analysis technology. Analytical and bioanalytical chemistry, 382, 669-678.
9. Vanden Bergh, G. and Arckens, L. (2004) Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Current Opinion in Biotechnology, 15, 38-43.
10. Maurer,M. H., Feldmann, R. E. Jr. Bromme, J. O. and Kalenka, A. (2005) Comparison of statistical approaches for the analysis of proteome expression data of differentiating neural stem cells. Journal of Proteome Research, 4, 96-100.
11. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F. and Whitehouse, C. M. (1989) Electrospray ionization for mass spectrometry of large biomolecules. Science, 246, 64-71.
12. Karas, M. and Hillenkamp, F. (1988) Laser desorption ionization of proteins with molecular masses exceeding 10 000 Da. Analytical Chemistry, 60, 2299-2301.
13. Hoogland, C., Sanchez, J. C., Tonella, L., Binz, P. A., Bairoch, A., Hochstrasser, D. F. and Appel, R. D. (2000) The 1999 SWISS-2DPAGE database update. Nucleic Acids Research, 28, 286-288.
14. Dalle-Donne, I., Scaloni, A. and Butterfield, D. A. (2006) Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases John Wiley & Sons, Inc., Hoboken, NJ.
15. Butterfield, D. A., Drake, J., Pocernich, C. and Castegna, A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends in Molecular Medicine, 7, 548-554.
16. Casserly, I. and Topol, E. (2004) Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet, 363, 1139-1146.
17. Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M. and Trojonowshi, J. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Medicine, 3, 67-72.
18. Cruts, M., van Duijn, C. M., Backhovens, H., Van den Broeck, M., Wehnert, A., Serneels, S., Sherrington, R., Hutton, M., Hardy, J., St. George-Hyslop, P. H., Hofman, A. and Van Broeckhoven, C. (1998) Estimation of the genetic contribution of presenilin-1 and-2 mutations in a population-based study of presenile Alzheimer disease. Human Molecular Genetics, 7, 43-51.
19. Mohmmad Abdul, H., Wenk, G. L., Gramling, M., Hauss-Wegrzyniak, B. and Butterfield, D. A. (2004) APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease. Neuroscience Letters, 368, 148-150.
20. Traykov, L., Rigaud, A. S., Baudic, S., Smagghe, A., Boller, F. and Forette, F. (2002) Apolipoprotein E epsilon 4 allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease. Journal of the Neurological Sciences, 203-204, 177-181.
21. Butterfield, D. A. (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radical Research, 36, 1307-1313.
22. Ho, G. J., Drego, R., Hakimian, E. and Masliah, E. (2005) Mechanisms of cell signaling and inflammation in Alzheimer's disease. Current Drug Targets-Inflammation and Allergy, 4, 247-256.
23. Hynd, M. R., Scott, H. L. and Dodd, P. R. (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochemistry International, 45, 583-595.
24. Markesbery, W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biology and Medicine, 23, 134-147.
25. Rego, A. C. and Oliveira, C. R. (2003) Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochemical Research, 28, 1563-1574.
26. Summers, W. K. (2004) Alzheimer's disease, oxidative injury, and cytokines. Journal of Alzheimer's Disease, 6, 651-657. discussion 673-681.
27. Tuppo, E. E. and Arias, H. R. (2005) The role of inflammation in Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 37, 289-305.
28. Ischiropoulos, H. and Beckman, J. S. (2003) Oxidative stress and nitration in neurodegeneration: cause, effect, or association? Journal of Clinical Investigation, 111, 163-169.
29. Stadtman, E. R. and Levine, R. L. (2003) Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids, 25, 207-218.
30. Mikkelsen, R. B. and Wardman, P. (2003) Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene, 22, 5734-5754.
31. Thannickal, V. J., Day, R. M., Klinz, S.G., Bastien, M. C., Larios, J. M. and Fanburg, B. L. (2000) Ras-dependent and-independent regulation of reactive oxygen species by mitogenic growth factors and TGF-beta1. Faseb Journal, 14, 1741-1748.
32. Sies, H. and Cadenas, E. (1985) Oxidative stress: damage to intact cells and organs. Philosophical transactions of the Royal Society of London. Series B: Biological Sciences, 311, 617-631.
33. Aksenov, M. Y., Aksenova, M. V., Butterfield, D.A., Geddes, J. W. and Markesbery, W. R. (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience, 103, 373-383.
34. Baynes, J. W. and Thorpe, S. R. (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radical Biology and Medicine, 28, 1708-1716.
35. Butterfield, D. A. and Lauderback, C. M. (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid betapeptide-associated free radical oxidative stress. Free Radical Biology and Medicine, 32, 1050-1060.
36. Butterfield, D. A. and Stadtman, E. R. (1997) Protein oxidation processes in aging brain. Advances in Cell Aging and Gerontology, 161-191.
37. Smith, M. A., Dunbar, C. E., Miller, E. J. and Perry, G. (1996) Trypsin interaction with the senile plaques of Alzheimer disease is mediated by beta-protein precursor. Molecular and Chemical Neuropathology, 27, 145-154.
38. Smith, M. A. and Perry, G. (1996) Alzheimer disease: protein-protein interaction and oxidative stress. Boletin de Estudios Medicos Y Biologicos, 44, 5-10.
39. Butterfield, D. A., Perluigi, M. and Sultana, R. (2006) Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. European Journal of Pharmacology, 545, 39-50.
40. Mohmmad Abdul, H., Sultana, R., Keller, J.N., St Clair, D. K., Markesbery, W. R. and Butterfield, D. A. (2006) Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. Journal of Neurochemistry, 96, 1322-1335.
41. Butterfield, D. A. (2004) Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Research, 1000, 1-7.
42. Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., Chiba, S., Atwood, C. S., Petersen, R. B. and Smith, M. A. (2001) Oxidative damage is the earliest event in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 60, 759-767.
43. Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S. and Perry, G. (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. Journal of Neuroscience, 17, 2653-2657.
44. Butterfield, D. A., Castegna, A., Lauderback, C. M. and Drake, J. (2002) Evidence that amyloid betapeptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiology of aging, 23, 655-664.
45. Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S. P. et al. (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. Journal of Neurochemistry, 65, 2146-2156.
46. Lovell, M. A. and Markesbery, W. R. (2001) Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Archives of Neurology, 58, 392-396.
47. Pratico, D., Lee, M. Y. V., Trojanowski, J. Q., Rokach, J. and Fitzgerald, G. A. (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. Journal of the Federation of American Societies for Experimental Biology, 12, 1777-1783.
48. Smith, M. A., Richey, P. L., Taneda, S., Kutty, R. K., Sayre, L. M., Monnier, V. M. and Perry, G. (1994) Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Annals of the New York Academy of Sciences, 738, 447-454.
49. Subbarao, K. V., Richardson, J. S. and Ang, L. C. (1990) Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. Journal of Neurochemistry, 55, 342-345.
50. Roberts, L. J. IIMontine, T. J., Markesbery, W. R., Tapper, A. R., Hardy, P., Chemtob, S., Dettbarn, W. D. and Morrow, J. D. (1998) Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. Journal of Biological Chemistry, 273, 13605-13612.
51. Drake, J., Link, C. D. and Butterfield, D. A. (2003) Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid bpeptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiology of Aging, 24, 415-420.
52. Obrenovich, M. E., Joseph, J. A., Atwood, C. S., Perry, G. and Smith, M. A. (2002) Amyloid-beta: a (life) preserver for the brain. Neurobiology of Aging, 23, 1097-1099.
53. Opazo, C., Huang, X., Cherny, R. A., Moir, R. D., Roher, A. E., White, A. R., Cappai, R., Masters, C. L. et al. (2002) Metalloenzyme-like activity of Alzheimer's disease b-amyloid. Cudependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). Journal of Biological Chemistry, 277, 40302-40308.
54. Zou, K., Gong, J. S., Yanagisawa, K. and Michikawa, M. (2002) A novel function of monomeric amyloid betaprotein serving as an antioxidant molecule against metal-induced oxidative damage. Journal of Neuroscience, 22, 4833-4841.
55. Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R. and Butterfield, D. A. (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. Journal of Neurochemistry, 78, 413-416.
56. Sultana, R. and Butterfield, D. A. (2004) Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochemical Research, 29, 2215-2220.
57. Boyd-Kimball, D., Sultana, R., Poon, H. F., Lynn, B. C., Casamenti, F., Pepeu, G., Klein, J. B. and Butterfield, D. A. (2005) Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience, 132, 313-324.
58. Butterfield, D. A., Poon, H. F., St Clair, D., Keller, J. N., Pierce, W. M., Klein, J. B. and Markesbery, W. R. (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiology of Disease, 22, 223-232.
59. Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R. and Butterfield, D. A. (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology and Medicine, 33, 562-571.
60. Castegna, A., Aksenov, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R. and Butterfield, D. A. (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. Journal of Neurochemistry, 82, 1524-1532.
61. Castegna, A., Thongboonkerd, V., Klein, J. B., Lynn, B., Markesbery, W. R. and Butterfield, D. A. (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. Journal of Neurochemistry, 85, 1394-1401.
62. Dalle-Donne, I., Scaloni, A., Giustarini, D., Cavarra, E., Tell, G., Lungarella, G., Colombo, R., Rossi, R. and Milzani, A. (2005) Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrometry Reviews, 24, 55-99.
63. Perluigi, M., Poon, H. F., Maragos, W., Pierce, W. M., Klein, J. B., Calabrese, V., Cini, C., DeMarco, C. and Butterfield, D. A. (2005) Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Molecular and Cellular Proteomics, 4, 1849-1861.
64. Poon, H. F., Shepherd, H. M., Reed, T. T., Calabrese, V., Stella, A. M., Pennisi, G., Cai, J., Pierce, W. M., Klein, J. B. and Buttectield, D. A. (2006) Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with agerelated impaired cellular processes: mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. Neurobiology of Aging, 27, 1020-1034.
65. Poon, H. F., Vaishnav, R. A., Butterfield, D. A., Getchell, M. L. and Getchell, T. V. (2005) Proteomic identification of differentially expressed proteins in the aging murine olfactory system and transcriptional analysis of the associated genes. Journal of Neurochemistry, 94, 380-392.
66. Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., Pierce, W. M., Klein, J. B., Markesbery, W. R., Zhou, X. Z., Lu, K. P. and Butterfield, D. A. (2006) Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiology of Aging, 27, 918-925.
67. Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., Pierce, W. M., Klein, J. B., Merchant, M., Markesbery, W. R. and Butterfield, D. A. (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiology of Aging, 27, 1564-1576.
68. Sultana, R., Perluigi, M. and Butterfield, D. A. (2006) Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). Journal of Chromatography B: Analytical Technologies in the Biomedical Life Sciences, 833, 3-11.
69. Sultana, R., Poon, H. F., Cai, J., Pierce, W. M., Merchant, M., Klein, J. B., Markesbery, W. R. and Butterfield, D. A. (2006) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiology of Disease, 22, 76-87.
70. Petersen, R. C. (2004) Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine, 256, 183-194.
71. Visser, P. J., Verhey, F. R., Ponds, R. W. and Jolles, J. (2001) Diagnosis of preclinical Alzheimer's disease in a clinical setting. International Psychogeriatrics, 13, 411-423.
72. Almkvist, O., Axelman, K., Basun, H., Jensen, M., Viitanen, M., Wahlund, L. O. and Lannfelt, L. (2003) Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment. Acta neurologica Scandinavica. Supplementum, 179, 77-82.
73. Nacmias, B., Piccini, C., Bagnoli, S., Tedde, A., Cellini, E., Bracco, L. and Sorbi, S. (2004) Brain-derived neurotrophic factor, apolipoprotein E genetic variants and cognitive performance in Alzheimer's disease. Neuroscience Letters, 367, 379-383.
74. Butterfield, D. A., Reed, T., Perluigi, M., DeMarco, C., Coccia, R., Cini, C. and Sultana, R. (2006) Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neuroscience Letters, 397, 170-173.
75. Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A. and Markesbery, W. R. (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology, 64, 1152-1156.
76. Markesbery, W. R., Kryscio, R. J., Lovell, M. A. and Morrow, J. D. (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Annals of Neurology, 58, 730-735.
77. Ding, Q., Markesbery, W. R., Cecarini, V. and Keller, J. N. (2006) Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochemical Research, 31, 705-710.
78. Wang, J., Markesbery, W. R. and Lovell, M. A. (2006) Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. Journal of Neurochemistry, 96, 825-832.
79. Barnes, D. E. and Yaffe, K. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. The New England Journal of Medicine, 353, 951-952 author reply 951-952.
80. Guidi, I., Galimberti, D., Lonati, S., Novembrino, C., Bamonti, F., Tiriticco, M., Fenoglio, C., Venturelli, E. et al. (2006) Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 27, 262-269.
81. Mecocci, P., Mariani, E., Cornacchiola, V. and Polidori, M. C. (2004) Antioxidants for the treatment of mild cognitive impairment. Neurological Research, 26, 598-602.
82. Rinaldi, P., Polidori, M. C., Metastasio, A., Mariani, E., Mattioli, P., Cherubini, A., Catani, M., Cecchetti, R. et al. (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiology of Aging, 24, 915-919.
83. Butterfield, D. A., Reed, T., Perluigi, M., De Marco, C., Coccia, R., Keller, J. N., Markesbery, W. R. and Sultana, R. (2007) Elevated Levels of 3-Nitrotyrosine in Brain From Subjects with Amnestic Mild Cognitive Impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Reserch, 1148, 242-248.
84. Vannucci, R. C. and Vannucci, S. J. (2000) Glucose metabolism in the developing brain. Seminars in Perinatology, 24, 107-115.
85. Castegna, A., Lauderback, C. M., Mohmmad-Abdul, H. and Butterfield, D. A. (2004) Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Research, 1004, 193-197.
86. Mohmmad Abdul, H. and Butterfield, D. A. (2005) Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. Biochimica Et Biophysica Acta, 1741, 140-148.
87. Planel, E., Miyasaka, T., Launey, T., Chui, D. H., Tanemura, K., Sato, S., Murayama, O., Ishiguro, K., Tatebayash, Y. and Taka Shima, A. (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. Journal of Neuroscience, 24, 2401-2411.
88. Messier, C. and Gagnon, M. (1996) Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behavioural Brain Research, 75, 1-11.
89. Rapoport, S. I. (1999) In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 249 (Suppl. 3), 46-55.
90. Vanhanen, M. and Soininen, H. (1998) Glucose intolerance, cognitive impairment and Alzheimer's disease. Current Opinion in Neurology, 11, 673-677.
91. Aksenova, M., Butterfield, D. A., Zhang, S. X., Underwood, M. and Geddes, J. W. (2002) Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. Journal of Neurotrauma, 19, 491-502.
92. Iwangoff, P., Armbruster, R., Enz, A. and Meier-Ruge, W. (1980) Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases. Mechanisms of Ageing and Development, 14, 203-209.
93. Meier-Ruge, W., Iwangoff, P. and Reichlmeier, K. (1984) Neurochemical enzyme changes in Alzheimer's and Pick's disease. Archives of Gerontology and Geriatrics, 3, 161-165.
94. Geddes, J. W., Pang, Z. and Wiley, D. H. (1996) Hippocampal damage and cytoskeletal disruption resulting from impaired energy metabolism. Implications for Alzheimer disease. Molecular and Chemical Neuropathology, 28, 65-74.
95. Sergeant, N., Wattez, A., Galvanvalencia, M., Ghestem, A., David, J. P., Lemoine, J., Sautiere, P. E., Dachary, J., Mazat, J. P., Michalshi, J. C., Velours, J., Mena-Lopez, R. and Delacourte, A. (2003) Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience, 117, 293-303.
96. Schagger, H. and Ohm, T. G. (1995) Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. European Journal of Biochemistry, 227, 916-921.
97. Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H. and Yankner, B. A. (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron, 33, 677-688.
98. Pancholi, V. (2001) Multifunctional alpha-enolase: its role in diseases. Cellular and Molecular Life Sciences, 58, 902-920.
99. Parnetti, L., Palumbo, B., Cardinali, L., Loreti, F., Chionne, F., Cecchetti, R. and Senin, U. (1995) Cerebrospinal fluid neuron-specific enolase in Alzheimer's disease and vascular dementia. Neuroscience Letters, 183, 43-45.
100. Mazzola, J. L. and Sirover, M. A. (2001) Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. Journal of Neurochemistry, 76, 442-449.
101. Sultana, R., Newman, S. F., Abdul, H.M., Cai, J., Pierce, W. M., Klein, J. B., Merchant, M. and Butterfield, D. A. (2006) Protective effect of D609 against amyloid-beta1-42-induced oxidative modification of neuronal proteins: redox proteomics study. Journal of Neuroscience Research, 84, 409-417.
102. Hernandez-Fonseca, K. and Montiel, T., Massieu (2005) Inhibition of glyceraldehyde-3-phsophate dehydrogenase by oxidative stress during metabolic inhibition leads to neuronal death in cultured hippocampal neurons. Society for Neuroscience Abstracts, 35.
103. Choi, J., Levey, A. I., Weintraub, S.T., Rees, H. D., Gearing, M., Chin, L. S. and Li, L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. Journal of Biological Chemistry, 279, 13256-13264.
104. Davies, M. J., Fu, S., Wang, H. and Dean, R. T. (1999) Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radical Biology and Medicine, 27, 1151-1163.
105. Halliwell, B. (2002) Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death. Annals of the New York Academy of Sciences, 962, 182-194.
106. Healy, D. G., Abou-Sleiman, P. M. and Wood, N. W. (2004) Genetic causes of Parkinson's disease: UCHL-1. Cell and Tissue Research, 318, 189-194.
107. McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P. and Olanow, C. W. (2003) Altered proteasomal function in sporadic Parkinson's disease. Experimental Neurology, 179, 38-46.
108. Stadtman, E. R., Oliver, C. N., Levine, R. L., Fucci, L. and Rivett, A. J. (1988) Implication of protein oxidation in protein turnover, aging, and oxygen toxicity. Basic Life Sciences, 49, 331-339.
109. Hyun, D. H., Gray, D. A., Halliwell, B. and Jenner, P. (2004) Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases. Journal of Neurochemistry, 90, 422-430.
110. Hyun, D. H., Lee, M. H., Halliwell, B. and Jenner, P. (2002) Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?. Journal of Neurochemistry, 83, 360-370.
111. Okada, K., Wangpoengtrakul, C., Osawa, T., Toyokuni, S., Tanaka, K. and Uchida, K. (1999) 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. Journal of Biological Chemistry, 274, 23787-23793.
112. Shringarpure, R., Grune, T., Sitte, N. and Davies, K. J. (2000) 4-Hydroxynonenal-modified amyloidbeta peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cellular and Molecular Life Sciences, 57, 1802-1809.
113. Gong, B., Cao, Z., Zheng, P., Vitolo, O. V., Liu, S., Staniszewski, A., Moolman, D., Zhang, H., Shelenshi, M. and Arancio, O. (2006) Ubiquitin hydrolase Uch-L1 rescues betaamyloid-induced decreases in synaptic function and contextual memory. Cell, 126, 775-788.
114. McClellan, A. J., Tam, S., Kaganovich, D. and Frydman, J. (2005) Protein quality control: chaperones culling corrupt conformations. Nature Cell Biology, 7, 736-741.
115. Esser, C., Alberti, S. and Hohfeld, J. (2004) Cooperation of molecular chaperones with the ubiquitin/ proteasome system. Biochimica Et Biophysica Acta, 1695, 171-188.
116. Daleke, D. L. and Lyles, J. V. (2000) Identification and purification of aminophospholipid flippases. Biochimica Et Biophysica Acta, 1486, 108-127.
117. Prasad, M. R., Lovell, M. A., Yatin, M., Dhillon, H. and Markesbery, W. R. (1998) Regional membrane phospholipid alterations in Alzheimer's disease. Neurochemical Research, 23, 81-88.
118. Lubec, G., Nonaka, M., Krapfenbauer, K., Gratzer, M., Cairns, N. and Fountoulakis, M. (1999) Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. Journal of Neural Transmission, 57, 161-177.
119. Coleman, P. D. and Flood, D. G. (1987) Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging, 8, 521-545.
120. Sultana, R., Boyd-Kimball, D., Cai, J., Pierce, W. M., Klein, J. B., Merchant, M., and Butterfield, D. A. (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. Journal of Alzheimer's Disease, 11, 153-164.
121. Stenbeck, G. (1998) Soluble NSFattachment proteins. International Journal of Biochemistry and Cell Biology, 30, 573-577.
122. Holzer, M., Gartner, U., Stobe, A., Hartig, W., Gruschka, H., Bruckner, M. K. and Arendt, T. (2002) Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathologica (Berl), 104, 471-481.
123. Kurt, M. A., Davies, D. C., Kidd, M., Duff, K. and Howlett, D. R. (2003) Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiology of Disease, 14, 89-97.
124. Ramakrishnan, P., Dickson, D. W. and Davies, P. (2003) Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. Neurobiology of Disease, 14, 251-264.
125. Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., Pierce, W. M., Klein, J. B., Markesbery, W. R., Zhou, X. Z., Lu, K. P. and Butterfield, D. A. (2006) Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiology of Aging, 27, 918-925.
126. Mandelkow, E. M., Thies, E., Trinczek, B., Biernat, J., and Mandelkow, E. (2004) MARK/PAR1 kinase is a regulator of microtubuledependent transport in axons. The Journal of Cell Biology, 167, 99-110.
127. Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P. and Lu, K. P. (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature, 399, 784-788.
128. Lu, K. P. (2000) Phosphorylationdependent prolyl isomerization: a novel cell cycle regulatory mechanism. Progress in Cell Cycle Research, 4, 83-96.
129. Nagy, Z., Esiri, M. M., Cato, A. M. and Smith, A. D. (1997) Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathologica (Berl), 94, 6-15.
130. Zhou, X. Z., Kops, O., Werner, A., Lu, P. J., Shen, M., Stoller, G., Kullertz, G., Stark, M., Fischer, G. and Lu, K. P. (2000) Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Molecular Cell, 6, 873-883.
131. Smith, P. D., O'Hare, M. J. and Park, D. S. (2004) Emerging pathogenic role for cyclin dependent kinases in neurodegeneration. Cell Cycle, 3, 289-291.
132. Pastorino, L., Sun, A., Lu, P. J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S. H., Li, X., Kia, W., Nicholson, L. K. and Lu, K. P. (2006) The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature, 440, 528-534.
133. Butterfield, D. A., Mohmmad-Abdul, H., Opii, W., Newman, S. F., Joshi, G., Ansari, M. A. and Sultana, R. (2006) Role of Pin1 in Alzheimer's disease. Journal of Neurochemistry, 98, 1699-1706.
134. Arendt, T. (2003) Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Progress in Neurobiology, 71, 83-248.
135. Ogawa, O., Lee, H. G., Zhu, X., Raina, A., Harris, P. L., Castellani, R. J., Perry, G. and Smith, M. A. (2003) Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging cell, 2, 105-110.
136. Sultana, R. and Butterfield, D. A. (2007) Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment. Neurochemical Research, 32, 655-662.
137. Sly, W. S. and Hu, P. Y. (1995) Human carbonic anhydrases and carbonic anhydrase deficiencies. Annual Review of Biochemistry, 64, 375-401.
138. Butterfield, D. A., Hensley, K., Cole, P., Subramaniam, R., Aksenov, M., Aksenova, M., Bummer, P. M., Haley, B. E. and Carney, J. M. (1997) Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. Journal of Neurochemistry, 68, 2451-2457.
139. Le Prince, G., Delaere, P., Fages, C., Lefrancois, T., Touret, M., Salanon, M. and Tardy, M. (1995) Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Neurochemical Research, 20, 859-862.
140. Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A. and Markesbery, W. R. (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proceedings of the National Academy of Sciences USA, 88, 10540-10543.